Jehad Saliba, MD
Pulmonary Disease · Kearny, NJNPI 1164480372
Payments from drug & device makers
Across 1,376 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Novo Nordisk$3K
- GSK$2K
- Boehringer Ingelheim$2K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $11K from 54 others
What the payments were for
- Food & beverage$24,63898%
- Education$4832%
- Gifts$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,134 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 15 | $2,569,034 |
| JardianceEmpagliflozin | 527 | $515,046 |
| OzempicSemaglutide | 301 | $349,529 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 351 | $279,387 |
| FarxigaDapagliflozin Propanediol | 212 | $238,282 |
| EliquisApixaban | 406 | $189,400 |
| JanuviaSitagliptin Phosphate | 167 | $186,357 |
| MounjaroTirzepatide | 138 | $160,290 |
| XareltoRivaroxaban | 144 | $132,476 |
| Dupixent PenDupilumab | 26 | $127,946 |
| Fasenra PenBenralizumab | 21 | $124,356 |
| Breo ElliptaFluticasone/Vilanterol | 221 | $120,386 |
| TrulicityDulaglutide | 61 | $105,491 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 111 | $98,562 |
| RybelsusSemaglutide | 54 | $85,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $545 | $2,569,03415 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $1,686 | $604,557640 claims |
| Novo NordiskOzempic, Rybelsus | $2,518 | $435,045355 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,089 | $418,266604 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $5,418 | $336,844323 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,078 | $265,782199 claims |
| MerckJanuvia, Janumet, Janumet Xr | $826 | $248,768228 claims |
| PfizerEliquis, Retacrit | $716 | $201,110430 claims |
| Johnson & JohnsonXarelto | $299 | $132,476144 claims |
| AbbVieCreon, Linzess, Restasis | $239 | $81,69282 claims |
| Astellas Pharma US IncMyrbetriq | $417 | $44,09869 claims |
| NovartisEntresto | $132 | $27,98431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Kearny
- Viren DesaiKearny$76K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.